Summary

The global Medication for Diabetes market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Medication for diabetes is a broad term that refers to any drug or treatment that helps people with diabetes manage their blood sugar levels. Blood sugar levels are affected by the amount of glucose (sugar) in the blood and the action of insulin, a hormone that helps cells use glucose for energy. People with diabetes either do not produce enough insulin, or their cells do not respond well to insulin, or both. This causes high blood sugar levels, which can lead to serious complications such as heart disease, kidney failure, nerve damage, and vision loss. Medication for diabetes aims to lower blood sugar levels to a healthy range and prevent or delay these complications.
In 2025, the North America Medication for Diabetes market was US$ million, while the Europe market stood at US$ million. North America accounted for % of the global market in 2025 and Europe for %. Europe’s share is expected to reach % by 2032, corresponding to a CAGR of % over the analysis period.
The global key players of Medication for Diabetes include Tonghua Dongbao, Gan & Lee Pharmaceuticals, Shandong Lukang Pharmaceutical, Otsuka Pharmaceutical, East China Pharmaceutical, Beilu Pharmaceutical, Furen Pharmaceutical, AstraZeneca, Novartis, Novo Nordisk, among others. In 2025, the top five players accounted for approximately % of global market revenue.
In terms of revenue, the top three players in North America accounted for about % of the market in 2025, while the top three in Europe held nearly %.
The global Medication for Diabetes market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.
Market Segmentation
By Company:
Tonghua Dongbao
Gan & Lee Pharmaceuticals
Shandong Lukang Pharmaceutical
Otsuka Pharmaceutical
East China Pharmaceutical
Beilu Pharmaceutical
Furen Pharmaceutical
AstraZeneca
Novartis
Novo Nordisk
Johnson & Johnson
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Merck
Sanofi
Pfizer
Astellas Pharma
Daiichi Sankyo
Biocon
Glenmark
Bayer AG
Takeda
Sun pharma
Segment by Type
Biguanides
Sulfonylureas
Thiazolidinedione
α-Glucosidase Inhibitors
DPP-4 Inhibitors
GLP-1 Receptor Agonists
SGLT-2 Inhibitors
Insulins
Segment by Application
Type 1 Diabetes Treatment
Type 2 Diabetes Treatment
By Region
Macro-Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Markets
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
(Additional regions can be customized based on client needs.)
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term)
Chapter 2: Quantitative analysis of Medication for Diabetes market size and growth potential at global, regional, and country levels
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus)
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities
Chapter 6: Regional revenue breakdown by company, type, application and customer
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Medication for Diabetes value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032
1.2.2 Biguanides
1.2.3 Sulfonylureas
1.2.4 Thiazolidinedione
1.2.5 α-Glucosidase Inhibitors
1.2.6 DPP-4 Inhibitors
1.2.7 GLP-1 Receptor Agonists
1.2.8 SGLT-2 Inhibitors
1.2.9 Insulins
1.3 Market by Application
1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032
1.3.2 Type 1 Diabetes Treatment
1.3.3 Type 2 Diabetes Treatment
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Medication for Diabetes Market Perspective (2021-2032)
2.2 Global Market Size by Region: 2021 vs 2025 vs 2032
2.3 Global Medication for Diabetes Market Share by Revenue, by Region (2021-2026)
2.4 Global Medication for Diabetes Revenue Forecast by Region (2027-2032)
2.5 Major Regions and Emerging Markets Analysis
2.5.1 North America Medication for Diabetes Market Size and Prospective (2021-2032)
2.5.2 Europe Medication for Diabetes Market Size and Prospective (2021-2032)
2.5.3 Asia-Pacific Medication for Diabetes Market Size and Prospective (2021-2032)
2.5.4 Latin America Medication for Diabetes Market Size and Prospective (2021-2032)
2.5.5 Middle East & Africa Medication for Diabetes Market Size and Prospective (2021-2032)
3 Breakdown Data by Type
3.1 Global Medication for Diabetes Historical Market Size by Type (2021-2026)
3.2 Global Medication for Diabetes Forecasted Market Size by Type (2027-2032)
3.3 Representative Players for Different Types of Medication for Diabetes
4 Breakdown Data by Application
4.1 Global Medication for Diabetes Historical Market Size by Application (2021-2026)
4.2 Global Medication for Diabetes Forecasted Market Size by Application (2027-2032)
4.3 New Sources of Growth in Medication for Diabetes Applications
5 Competitive Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Medication for Diabetes Players by Revenue (2021-2026)
5.1.2 Global Medication for Diabetes Market Share by Revenue, by Players (2021-2026)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Medication for Diabetes Revenue
5.4 Global Medication for Diabetes Market Concentration Analysis
5.4.1 Global Medication for Diabetes Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Medication for Diabetes Revenue in 2025
5.5 Global Key Players of Medication for Diabetes Head Offices and Areas Served
5.6 Global Key Players of Medication for Diabetes, Product and Application
5.7 Global Key Players of Medication for Diabetes, Date of Entry into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Medication for Diabetes Revenue by Company (2021-2026)
6.1.2 North America Market Size by Type
6.1.2.1 North America Medication for Diabetes Market Size by Type (2021-2026)
6.1.2.2 North America Medication for Diabetes Market Share by Type (2021-2026)
6.1.3 North America Market Size by Application
6.1.3.1 North America Medication for Diabetes Market Size by Application (2021-2026)
6.1.3.2 North America Medication for Diabetes Market Share by Application (2021-2026)
6.1.4 North America Medication for Diabetes Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Medication for Diabetes Revenue by Company (2021-2026)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Medication for Diabetes Market Size by Type (2021-2026)
6.2.2.2 Europe Medication for Diabetes Market Share by Type (2021-2026)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Medication for Diabetes Market Size by Application (2021-2026)
6.2.3.2 Europe Medication for Diabetes Market Share by Application (2021-2026)
6.2.4 Europe Medication for Diabetes Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 Asia-Pacific Market: Players, Segments, Downstream and Major Customers
6.3.1 Asia-Pacific Medication for Diabetes Revenue by Company (2021-2026)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific Medication for Diabetes Market Size by Type (2021-2026)
6.3.2.2 Asia-Pacific Medication for Diabetes Market Share by Type (2021-2026)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific Medication for Diabetes Market Size by Application (2021-2026)
6.3.3.2 Asia-Pacific Medication for Diabetes Market Share by Application (2021-2026)
6.3.4 Asia-Pacific Medication for Diabetes Major Customers
6.3.5 Asia-Pacific Market Trends and Opportunities
6.4 Latin America Market: Players, Segments, Downstream and Major Customers
6.4.1 Latin America Medication for Diabetes Revenue by Company (2021-2026)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America Medication for Diabetes Market Size by Type (2021-2026)
6.4.2.2 Latin America Medication for Diabetes Market Share by Type (2021-2026)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America Medication for Diabetes Market Size by Application (2021-2026)
6.4.3.2 Latin America Medication for Diabetes Market Share by Application (2021-2026)
6.4.4 Latin America Medication for Diabetes Major Customers
6.4.5 Latin America Market Trends and Opportunities
6.5 Middle East & Africa Market: Players, Segments, Downstream and Major Customers
6.5.1 Middle East & Africa Medication for Diabetes Revenue by Company (2021-2026)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa Medication for Diabetes Market Size by Type (2021-2026)
6.5.2.2 Middle East & Africa Medication for Diabetes Market Share by Type (2021-2026)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa Medication for Diabetes Market Size by Application (2021-2026)
6.5.3.2 Middle East & Africa Medication for Diabetes Market Share by Application (2021-2026)
6.5.4 Middle East & Africa Medication for Diabetes Major Customers
6.5.5 Middle East & Africa Market Trends and Opportunities
7 Key Player Profiles
7.1 Tonghua Dongbao
7.1.1 Tonghua Dongbao Company Details
7.1.2 Tonghua Dongbao Business Overview
7.1.3 Tonghua Dongbao Medication for Diabetes Introduction
7.1.4 Tonghua Dongbao Revenue in Medication for Diabetes Business (2021-2026)
7.1.5 Tonghua Dongbao Recent Development
7.2 Gan & Lee Pharmaceuticals
7.2.1 Gan & Lee Pharmaceuticals Company Details
7.2.2 Gan & Lee Pharmaceuticals Business Overview
7.2.3 Gan & Lee Pharmaceuticals Medication for Diabetes Introduction
7.2.4 Gan & Lee Pharmaceuticals Revenue in Medication for Diabetes Business (2021-2026)
7.2.5 Gan & Lee Pharmaceuticals Recent Development
7.3 Shandong Lukang Pharmaceutical
7.3.1 Shandong Lukang Pharmaceutical Company Details
7.3.2 Shandong Lukang Pharmaceutical Business Overview
7.3.3 Shandong Lukang Pharmaceutical Medication for Diabetes Introduction
7.3.4 Shandong Lukang Pharmaceutical Revenue in Medication for Diabetes Business (2021-2026)
7.3.5 Shandong Lukang Pharmaceutical Recent Development
7.4 Otsuka Pharmaceutical
7.4.1 Otsuka Pharmaceutical Company Details
7.4.2 Otsuka Pharmaceutical Business Overview
7.4.3 Otsuka Pharmaceutical Medication for Diabetes Introduction
7.4.4 Otsuka Pharmaceutical Revenue in Medication for Diabetes Business (2021-2026)
7.4.5 Otsuka Pharmaceutical Recent Development
7.5 East China Pharmaceutical
7.5.1 East China Pharmaceutical Company Details
7.5.2 East China Pharmaceutical Business Overview
7.5.3 East China Pharmaceutical Medication for Diabetes Introduction
7.5.4 East China Pharmaceutical Revenue in Medication for Diabetes Business (2021-2026)
7.5.5 East China Pharmaceutical Recent Development
7.6 Beilu Pharmaceutical
7.6.1 Beilu Pharmaceutical Company Details
7.6.2 Beilu Pharmaceutical Business Overview
7.6.3 Beilu Pharmaceutical Medication for Diabetes Introduction
7.6.4 Beilu Pharmaceutical Revenue in Medication for Diabetes Business (2021-2026)
7.6.5 Beilu Pharmaceutical Recent Development
7.7 Furen Pharmaceutical
7.7.1 Furen Pharmaceutical Company Details
7.7.2 Furen Pharmaceutical Business Overview
7.7.3 Furen Pharmaceutical Medication for Diabetes Introduction
7.7.4 Furen Pharmaceutical Revenue in Medication for Diabetes Business (2021-2026)
7.7.5 Furen Pharmaceutical Recent Development
7.8 AstraZeneca
7.8.1 AstraZeneca Company Details
7.8.2 AstraZeneca Business Overview
7.8.3 AstraZeneca Medication for Diabetes Introduction
7.8.4 AstraZeneca Revenue in Medication for Diabetes Business (2021-2026)
7.8.5 AstraZeneca Recent Development
7.9 Novartis
7.9.1 Novartis Company Details
7.9.2 Novartis Business Overview
7.9.3 Novartis Medication for Diabetes Introduction
7.9.4 Novartis Revenue in Medication for Diabetes Business (2021-2026)
7.9.5 Novartis Recent Development
7.10 Novo Nordisk
7.10.1 Novo Nordisk Company Details
7.10.2 Novo Nordisk Business Overview
7.10.3 Novo Nordisk Medication for Diabetes Introduction
7.10.4 Novo Nordisk Revenue in Medication for Diabetes Business (2021-2026)
7.10.5 Novo Nordisk Recent Development
7.11 Johnson & Johnson
7.11.1 Johnson & Johnson Company Details
7.11.2 Johnson & Johnson Business Overview
7.11.3 Johnson & Johnson Medication for Diabetes Introduction
7.11.4 Johnson & Johnson Revenue in Medication for Diabetes Business (2021-2026)
7.11.5 Johnson & Johnson Recent Development
7.12 Boehringer Ingelheim
7.12.1 Boehringer Ingelheim Company Details
7.12.2 Boehringer Ingelheim Business Overview
7.12.3 Boehringer Ingelheim Medication for Diabetes Introduction
7.12.4 Boehringer Ingelheim Revenue in Medication for Diabetes Business (2021-2026)
7.12.5 Boehringer Ingelheim Recent Development
7.13 Bristol-Myers Squibb
7.13.1 Bristol-Myers Squibb Company Details
7.13.2 Bristol-Myers Squibb Business Overview
7.13.3 Bristol-Myers Squibb Medication for Diabetes Introduction
7.13.4 Bristol-Myers Squibb Revenue in Medication for Diabetes Business (2021-2026)
7.13.5 Bristol-Myers Squibb Recent Development
7.14 Eli Lilly
7.14.1 Eli Lilly Company Details
7.14.2 Eli Lilly Business Overview
7.14.3 Eli Lilly Medication for Diabetes Introduction
7.14.4 Eli Lilly Revenue in Medication for Diabetes Business (2021-2026)
7.14.5 Eli Lilly Recent Development
7.15 Merck
7.15.1 Merck Company Details
7.15.2 Merck Business Overview
7.15.3 Merck Medication for Diabetes Introduction
7.15.4 Merck Revenue in Medication for Diabetes Business (2021-2026)
7.15.5 Merck Recent Development
7.16 Sanofi
7.16.1 Sanofi Company Details
7.16.2 Sanofi Business Overview
7.16.3 Sanofi Medication for Diabetes Introduction
7.16.4 Sanofi Revenue in Medication for Diabetes Business (2021-2026)
7.16.5 Sanofi Recent Development
7.17 Pfizer
7.17.1 Pfizer Company Details
7.17.2 Pfizer Business Overview
7.17.3 Pfizer Medication for Diabetes Introduction
7.17.4 Pfizer Revenue in Medication for Diabetes Business (2021-2026)
7.17.5 Pfizer Recent Development
7.18 Astellas Pharma
7.18.1 Astellas Pharma Company Details
7.18.2 Astellas Pharma Business Overview
7.18.3 Astellas Pharma Medication for Diabetes Introduction
7.18.4 Astellas Pharma Revenue in Medication for Diabetes Business (2021-2026)
7.18.5 Astellas Pharma Recent Development
7.19 Daiichi Sankyo
7.19.1 Daiichi Sankyo Company Details
7.19.2 Daiichi Sankyo Business Overview
7.19.3 Daiichi Sankyo Medication for Diabetes Introduction
7.19.4 Daiichi Sankyo Revenue in Medication for Diabetes Business (2021-2026)
7.19.5 Daiichi Sankyo Recent Development
7.20 Biocon
7.20.1 Biocon Company Details
7.20.2 Biocon Business Overview
7.20.3 Biocon Medication for Diabetes Introduction
7.20.4 Biocon Revenue in Medication for Diabetes Business (2021-2026)
7.20.5 Biocon Recent Development
7.21 Glenmark
7.21.1 Glenmark Company Details
7.21.2 Glenmark Business Overview
7.21.3 Glenmark Medication for Diabetes Introduction
7.21.4 Glenmark Revenue in Medication for Diabetes Business (2021-2026)
7.21.5 Glenmark Recent Development
7.22 Bayer AG
7.22.1 Bayer AG Company Details
7.22.2 Bayer AG Business Overview
7.22.3 Bayer AG Medication for Diabetes Introduction
7.22.4 Bayer AG Revenue in Medication for Diabetes Business (2021-2026)
7.22.5 Bayer AG Recent Development
7.23 Takeda
7.23.1 Takeda Company Details
7.23.2 Takeda Business Overview
7.23.3 Takeda Medication for Diabetes Introduction
7.23.4 Takeda Revenue in Medication for Diabetes Business (2021-2026)
7.23.5 Takeda Recent Development
7.24 Sun pharma
7.24.1 Sun pharma Company Details
7.24.2 Sun pharma Business Overview
7.24.3 Sun pharma Medication for Diabetes Introduction
7.24.4 Sun pharma Revenue in Medication for Diabetes Business (2021-2026)
7.24.5 Sun pharma Recent Development
8 Medication for Diabetes Market Dynamics
8.1 Medication for Diabetes Industry Trends
8.2 Medication for Diabetes Market Drivers
8.3 Medication for Diabetes Market Challenges
8.4 Medication for Diabetes Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Medication for Diabetes Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Global Medication for Diabetes Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 3. Global Market Medication for Diabetes Market Size (US$ Million) by Region:2021 vs 2025 vs 2032
Table 4. Global Medication for Diabetes Revenue (US$ Million) Market Share by Region (2021-2026)
Table 5. Global Medication for Diabetes Revenue Share by Region (2021-2026)
Table 6. Global Medication for Diabetes Revenue (US$ Million) Forecast by Region (2027-2032)
Table 7. Global Medication for Diabetes Revenue Share Forecast by Region (2027-2032)
Table 8. Global Medication for Diabetes Market Size by Type (2021-2026) & (US$ Million)
Table 9. Global Medication for Diabetes Market Share by Revenue, by Type (2021-2026)
Table 10. Global Medication for Diabetes Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 11. Global Medication for Diabetes Market Share by Revenue, by Type (2027-2032)
Table 12. Representative Players of Each Type
Table 13. Global Medication for Diabetes Market Size by Application (2021-2026) & (US$ Million)
Table 14. Global Medication for Diabetes Market Share by Revenue, by Application (2021-2026)
Table 15. Global Medication for Diabetes Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 16. Global Medication for Diabetes Market Share by Revenue, by Application (2027-2032)
Table 17. New Sources of Growth in Medication for Diabetes Applications
Table 18. Global Medication for Diabetes Revenue by Players (2021-2026) & (US$ Million)
Table 19. Global Medication for Diabetes Market Share by Players (2021-2026)
Table 20. Global Top Medication for Diabetes Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Medication for Diabetes as of 2025)
Table 21. Ranking of Global Top Medication for Diabetes Companies by Revenue (US$ Million) in 2025
Table 22. Global 5 Largest Players Market Share by Medication for Diabetes Revenue (CR5 and HHI) & (2021-2026)
Table 23. Global Key Players of Medication for Diabetes, Headquarters and Area Served
Table 24. Global Key Players of Medication for Diabetes, Product and Application
Table 25. Global Key Players of Medication for Diabetes, Date of Entry into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Medication for Diabetes Revenue by Company (2021-2026) & (US$ Million)
Table 28. North America Medication for Diabetes Market Share by Revenue, by Company (2021-2026)
Table 29. North America Medication for Diabetes Market Size by Type (2021-2026) & (US$ Million)
Table 30. North America Medication for Diabetes Market Size by Application (2021-2026) & (US$ Million)
Table 31. Europe Medication for Diabetes Revenue by Company (2021-2026) & (US$ Million)
Table 32. Europe Medication for Diabetes Market Share by Revenue, by Company (2021-2026)
Table 33. Europe Medication for Diabetes Market Size by Type (2021-2026) & (US$ Million)
Table 34. Europe Medication for Diabetes Market Size by Application (2021-2026) & (US$ Million)
Table 35. Asia-Pacific Medication for Diabetes Revenue by Company (2021-2026) & (US$ Million)
Table 36. Asia-Pacific Medication for Diabetes Market Share by Revenue, by Company (2021-2026)
Table 37. Asia-Pacific Medication for Diabetes Market Size by Type (2021-2026) & (US$ Million)
Table 38. Asia-Pacific Medication for Diabetes Market Size by Application (2021-2026) & (US$ Million)
Table 39. Latin America Medication for Diabetes Revenue by Company (2021-2026) & (US$ Million)
Table 40. Latin America Medication for Diabetes Market Share by Revenue, by Company (2021-2026)
Table 41. Latin America Medication for Diabetes Market Size by Type (2021-2026) & (US$ Million)
Table 42. Latin America Medication for Diabetes Market Size by Application (2021-2026) & (US$ Million)
Table 43. Middle East & Africa Medication for Diabetes Revenue by Company (2021-2026) & (US$ Million)
Table 44. Middle East & Africa Medication for Diabetes Market Share by Revenue, by Company (2021-2026)
Table 45. Middle East & Africa Medication for Diabetes Market Size by Type (2021-2026) & (US$ Million)
Table 46. Middle East & Africa Medication for Diabetes Market Size by Application (2021-2026) & (US$ Million)
Table 47. Tonghua Dongbao Company Details
Table 48. Tonghua Dongbao Business Overview
Table 49. Tonghua Dongbao Medication for Diabetes Product
Table 50. Tonghua Dongbao Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 51. Tonghua Dongbao Recent Development
Table 52. Gan & Lee Pharmaceuticals Company Details
Table 53. Gan & Lee Pharmaceuticals Business Overview
Table 54. Gan & Lee Pharmaceuticals Medication for Diabetes Product
Table 55. Gan & Lee Pharmaceuticals Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 56. Gan & Lee Pharmaceuticals Recent Development
Table 57. Shandong Lukang Pharmaceutical Company Details
Table 58. Shandong Lukang Pharmaceutical Business Overview
Table 59. Shandong Lukang Pharmaceutical Medication for Diabetes Product
Table 60. Shandong Lukang Pharmaceutical Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 61. Shandong Lukang Pharmaceutical Recent Development
Table 62. Otsuka Pharmaceutical Company Details
Table 63. Otsuka Pharmaceutical Business Overview
Table 64. Otsuka Pharmaceutical Medication for Diabetes Product
Table 65. Otsuka Pharmaceutical Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 66. Otsuka Pharmaceutical Recent Development
Table 67. East China Pharmaceutical Company Details
Table 68. East China Pharmaceutical Business Overview
Table 69. East China Pharmaceutical Medication for Diabetes Product
Table 70. East China Pharmaceutical Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 71. East China Pharmaceutical Recent Development
Table 72. Beilu Pharmaceutical Company Details
Table 73. Beilu Pharmaceutical Business Overview
Table 74. Beilu Pharmaceutical Medication for Diabetes Product
Table 75. Beilu Pharmaceutical Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 76. Beilu Pharmaceutical Recent Development
Table 77. Furen Pharmaceutical Company Details
Table 78. Furen Pharmaceutical Business Overview
Table 79. Furen Pharmaceutical Medication for Diabetes Product
Table 80. Furen Pharmaceutical Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 81. Furen Pharmaceutical Recent Development
Table 82. AstraZeneca Company Details
Table 83. AstraZeneca Business Overview
Table 84. AstraZeneca Medication for Diabetes Product
Table 85. AstraZeneca Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 86. AstraZeneca Recent Development
Table 87. Novartis Company Details
Table 88. Novartis Business Overview
Table 89. Novartis Medication for Diabetes Product
Table 90. Novartis Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 91. Novartis Recent Development
Table 92. Novo Nordisk Company Details
Table 93. Novo Nordisk Business Overview
Table 94. Novo Nordisk Medication for Diabetes Product
Table 95. Novo Nordisk Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 96. Novo Nordisk Recent Development
Table 97. Johnson & Johnson Company Details
Table 98. Johnson & Johnson Business Overview
Table 99. Johnson & Johnson Medication for Diabetes Product
Table 100. Johnson & Johnson Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 101. Johnson & Johnson Recent Development
Table 102. Boehringer Ingelheim Company Details
Table 103. Boehringer Ingelheim Business Overview
Table 104. Boehringer Ingelheim Medication for Diabetes Product
Table 105. Boehringer Ingelheim Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 106. Boehringer Ingelheim Recent Development
Table 107. Bristol-Myers Squibb Company Details
Table 108. Bristol-Myers Squibb Business Overview
Table 109. Bristol-Myers Squibb Medication for Diabetes Product
Table 110. Bristol-Myers Squibb Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 111. Bristol-Myers Squibb Recent Development
Table 112. Eli Lilly Company Details
Table 113. Eli Lilly Business Overview
Table 114. Eli Lilly Medication for Diabetes Product
Table 115. Eli Lilly Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 116. Eli Lilly Recent Development
Table 117. Merck Company Details
Table 118. Merck Business Overview
Table 119. Merck Medication for Diabetes Product
Table 120. Merck Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 121. Merck Recent Development
Table 122. Sanofi Company Details
Table 123. Sanofi Business Overview
Table 124. Sanofi Medication for Diabetes Product
Table 125. Sanofi Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 126. Sanofi Recent Development
Table 127. Pfizer Company Details
Table 128. Pfizer Business Overview
Table 129. Pfizer Medication for Diabetes Product
Table 130. Pfizer Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 131. Pfizer Recent Development
Table 132. Astellas Pharma Company Details
Table 133. Astellas Pharma Business Overview
Table 134. Astellas Pharma Medication for Diabetes Product
Table 135. Astellas Pharma Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 136. Astellas Pharma Recent Development
Table 137. Daiichi Sankyo Company Details
Table 138. Daiichi Sankyo Business Overview
Table 139. Daiichi Sankyo Medication for Diabetes Product
Table 140. Daiichi Sankyo Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 141. Daiichi Sankyo Recent Development
Table 142. Biocon Company Details
Table 143. Biocon Business Overview
Table 144. Biocon Medication for Diabetes Product
Table 145. Biocon Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 146. Biocon Recent Development
Table 147. Glenmark Company Details
Table 148. Glenmark Business Overview
Table 149. Glenmark Medication for Diabetes Product
Table 150. Glenmark Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 151. Glenmark Recent Development
Table 152. Bayer AG Company Details
Table 153. Bayer AG Business Overview
Table 154. Bayer AG Medication for Diabetes Product
Table 155. Bayer AG Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 156. Bayer AG Recent Development
Table 157. Takeda Company Details
Table 158. Takeda Business Overview
Table 159. Takeda Medication for Diabetes Product
Table 160. Takeda Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 161. Takeda Recent Development
Table 162. Sun pharma Company Details
Table 163. Sun pharma Business Overview
Table 164. Sun pharma Medication for Diabetes Product
Table 165. Sun pharma Revenue in Medication for Diabetes Business (2021-2026) & (US$ Million)
Table 166. Sun pharma Recent Development
Table 167. Medication for Diabetes Market Trends
Table 168. Medication for Diabetes Market Drivers
Table 169. Medication for Diabetes Market Challenges
Table 170. Medication for Diabetes Market Restraints
Table 171. Research Programs/Design for This Report
Table 172. Key Data Information from Secondary Sources
Table 173. Key Data Information from Primary Sources


List of Figures
Figure 1. Medication for Diabetes Product Picture
Figure 2. Global Medication for Diabetes Market Share by Type: 2025 vs 2032
Figure 3. Biguanides Features
Figure 4. Sulfonylureas Features
Figure 5. Thiazolidinedione Features
Figure 6. α-Glucosidase Inhibitors Features
Figure 7. DPP-4 Inhibitors Features
Figure 8. GLP-1 Receptor Agonists Features
Figure 9. SGLT-2 Inhibitors Features
Figure 10. Insulins Features
Figure 11. Global Medication for Diabetes Market Share by Application: 2025 vs 2032
Figure 12. Type 1 Diabetes Treatment
Figure 13. Type 2 Diabetes Treatment
Figure 14. Medication for Diabetes Report Years Considered
Figure 15. Global Medication for Diabetes Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 16. Global Medication for Diabetes Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 17. Global Medication for Diabetes Market Share by Revenue, by Region: 2021 vs 2025
Figure 18. North America Medication for Diabetes Revenue (US$ Million) Growth Rate (2021-2032)
Figure 19. Europe Medication for Diabetes Revenue (US$ Million) Growth Rate (2021-2032)
Figure 20. Asia-Pacific Medication for Diabetes Revenue (US$ Million) Growth Rate (2021-2032)
Figure 21. Latin America Medication for Diabetes Revenue (US$ Million) Growth Rate (2021-2032)
Figure 22. Middle East & Africa Medication for Diabetes Revenue (US$ Million) Growth Rate (2021-2032)
Figure 23. Global Medication for Diabetes Market Share by Players in 2025
Figure 24. Global Top Medication for Diabetes Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Medication for Diabetes as of 2025)
Figure 25. The Top 10 and 5 Players Market Share by Medication for Diabetes Revenue in 2025
Figure 26. North America Medication for Diabetes Market Share by Type (2021-2026)
Figure 27. North America Medication for Diabetes Market Share by Application (2021-2026)
Figure 28. Europe Medication for Diabetes Market Share by Type (2021-2026)
Figure 29. Europe Medication for Diabetes Market Share by Application (2021-2026)
Figure 30. Asia-Pacific Medication for Diabetes Market Share by Type (2021-2026)
Figure 31. Asia-Pacific Medication for Diabetes Market Share by Application (2021-2026)
Figure 32. Latin America Medication for Diabetes Market Share by Type (2021-2026)
Figure 33. Latin America Medication for Diabetes Market Share by Application (2021-2026)
Figure 34. Middle East & Africa Medication for Diabetes Market Share by Type (2021-2026)
Figure 35. Middle East & Africa Medication for Diabetes Market Share by Application (2021-2026)
Figure 36. Tonghua Dongbao Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 37. Gan & Lee Pharmaceuticals Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 38. Shandong Lukang Pharmaceutical Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 39. Otsuka Pharmaceutical Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 40. East China Pharmaceutical Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 41. Beilu Pharmaceutical Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 42. Furen Pharmaceutical Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 43. AstraZeneca Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 44. Novartis Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 45. Novo Nordisk Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 46. Johnson & Johnson Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 47. Boehringer Ingelheim Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 48. Bristol-Myers Squibb Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 49. Eli Lilly Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 50. Merck Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 51. Sanofi Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 52. Pfizer Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 53. Astellas Pharma Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 54. Daiichi Sankyo Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 55. Biocon Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 56. Glenmark Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 57. Bayer AG Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 58. Takeda Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 59. Sun pharma Revenue Growth Rate in Medication for Diabetes Business (2021-2026)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed